SEC

2021 Allergic Conjunctivitis Report on Drugs in Development - ResearchAndMarkets.com

Thursday, September 23, 2021 - 10:14am

The "Allergic Conjunctivitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allergic Conjunctivitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.
  • This report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects.

KVH Provides Global VSAT Connectivity to A.M. Nomikos Vessels and Crew

Thursday, September 23, 2021 - 8:00am

MIDDLETOWN, R.I., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KVH Industries, Inc., (Nasdaq: KVHI), announced today that leading Greek shipmanager A.M. Nomikos has chosen KVH AgilePlans to provide VSAT connectivity for crew welfare and vessel operations.

Key Points: 
  • MIDDLETOWN, R.I., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KVH Industries, Inc., (Nasdaq: KVHI), announced today that leading Greek shipmanager A.M. Nomikos has chosen KVH AgilePlans to provide VSAT connectivity for crew welfare and vessel operations.
  • KVH understands the commercial maritime industry and its challenges and thats why the KVH AgilePlans program is so successful.
  • The Nomikos vessels will also use Iridium Certus as a backup companion solution with the KVH system.
  • A market leader in maritime VSAT, KVH designs, manufactures, and provides connectivity and content services globally.

Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors

Thursday, September 23, 2021 - 7:45am

The New Shares will represent 5.1% of the share capital of the Company upon completion of the transaction.

Key Points: 
  • The New Shares will represent 5.1% of the share capital of the Company upon completion of the transaction.
  • It is anticipated that the settlement and delivery of the New Shares will take place on September 27, 2021.
  • Prospective investors should read the base prospectus and the accompanying sales agreement prospectus, together with the documents incorporated by reference therein.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

Caledonia Mining Corporation Plc: Caledonia acquires the 940,000 oz Maligreen project in Zimbabwe

Thursday, September 23, 2021 - 7:00am

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No.

Key Points: 
  • The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No.
  • This news release is not an offer of the shares of Caledonia for sale in the United States or elsewhere.
  • These standards differ from the requirements of the United States Securities and Exchange Commission (the SEC) applicable to domestic United States reporting companies.
  • A technical report prepared in accordance with NI 43-101 for Maligreen will be filed by the Company on SEDAR ( www.sedar.com ) within 45 days of this news release.

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Thursday, September 23, 2021 - 6:00am

Disclaimer on forward-looking information and risk factors:

Key Points: 
  • Disclaimer on forward-looking information and risk factors:
    This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including believe, potential, expect and will and similar expressions, is intended to identify forward-looking statements.
  • Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.
  • These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys commercialization efforts, the Companys continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Companys business, financial condition and results of operations.
  • This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

The9 Limited, Polygon, and Protocol Labs Announced Ecosystem Collaboration on NFTSTAR and GameFi Play-to-earn Projects

Thursday, September 23, 2021 - 5:00am

SINGAPORE, Sept. 23, 2021 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established internet company, Polygon, an Ethereum scaling platform, and Protocol Labs, Inc. ("Protocol Labs"), a major contributor of open-source projects including InterPlanetary File System, or IPFS, and Filecoin, today announced that they are forming an ecosystem collaboration on The9's Non-Fungible Token (NFT) platform NFTSTAR and GameFi Play-to-Earn projects.

Key Points: 
  • SINGAPORE, Sept. 23, 2021 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established internet company, Polygon, an Ethereum scaling platform, and Protocol Labs, Inc. ("Protocol Labs"), a major contributor of open-source projects including InterPlanetary File System, or IPFS, and Filecoin, today announced that they are forming an ecosystem collaboration on The9's Non-Fungible Token (NFT) platform NFTSTAR and GameFi Play-to-Earn projects.
  • The9 announced NFTSTAR as one of its core businesses in August 2021.
  • NFTSTAR will accept general payment methods, such as credit cards, to make it easy for mainstream consumers to participate.
  • The three parties have formed an ecosystem collaboration on NFTSTAR and GameFi Projects including but not limited to the following areas:
    The9's NFTSTAR platform and the GameFi projects developed by The9 will consider Polygon as the first priority of public blockchain to support the technical operation and maintenance.

Argo Announces Pricing of Initial Public Offering

Thursday, September 23, 2021 - 4:49am

Argo Blockchain Plc (LSE: ARB; OTCQX: ARBKF), (Argo or the Company), a global leader in sustainable blockchain infrastructure and cryptocurrency mining, is pleased to announce the pricing of its initial public offering of 7,500,000 American Depositary Shares ("ADSs"), representing an aggregate of 75,000,000 ordinary shares, at a public offering price of $15.00 per ADS.

Key Points: 
  • Argo Blockchain Plc (LSE: ARB; OTCQX: ARBKF), (Argo or the Company), a global leader in sustainable blockchain infrastructure and cryptocurrency mining, is pleased to announce the pricing of its initial public offering of 7,500,000 American Depositary Shares ("ADSs"), representing an aggregate of 75,000,000 ordinary shares, at a public offering price of $15.00 per ADS.
  • In addition, Argo Blockchain has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ADSs at the public offering price, less underwriting discounts, and commissions.
  • The ADSs are being offered in a registered public offering in the United States (the "Offering").
  • Davidson & Co., Ladenburg Thalmann, Roth Capital Partners, finnCap Ltd, and Tennyson Securities are acting as co-managers for the Offering.

Hyatt Announces Pricing of Public Offering of 7,000,000 Shares of Common Stock

Thursday, September 23, 2021 - 3:18am

Hyatt Hotels Corporation (Hyatt or the Company) (NYSE: H), a leading global hospitality company, announced today the pricing of its underwritten registered public offering of 7,000,000 shares of its Class A common stock at a public offering price of $74.50 per share.

Key Points: 
  • Hyatt Hotels Corporation (Hyatt or the Company) (NYSE: H), a leading global hospitality company, announced today the pricing of its underwritten registered public offering of 7,000,000 shares of its Class A common stock at a public offering price of $74.50 per share.
  • The underwriters have a 30-day option to purchase up to an additional 1,050,000 shares from the Company at the public offering price, less the underwriting discount.
  • The shares are expected to be delivered on or about September 27, 2021, subject to customary closing conditions.
  • The Company's subsidiaries operate, manage, franchise, own, lease, develop, license, or provide services to hotels, resorts, branded residences, and vacation ownership properties, including under the Park Hyatt, Miraval, Grand Hyatt, Alila, Andaz, The Unbound Collection by Hyatt, Destination by Hyatt, Hyatt Regency, Hyatt, Hyatt Ziva, Hyatt Zilara, Thompson Hotels, Hyatt Centric, Caption by Hyatt, JdV by Hyatt, Hyatt House, Hyatt Place, tommie, UrCove, and Hyatt Residence Club brand names, and operates the World of Hyatt loyalty program that provides distinct benefits and exclusive experiences to its valued members.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AdaptHealth, Koninklijke Philips, PayPal, and Boston Beer and Encourages Investors to Contact the Firm

Thursday, September 23, 2021 - 2:31am

On this news, AdaptHealths stock price fell$1.51per share, or 5.93%, to close at$23.96per share onJuly 19, 2021.

Key Points: 
  • On this news, AdaptHealths stock price fell$1.51per share, or 5.93%, to close at$23.96per share onJuly 19, 2021.
  • On this news,Philips stock price fell $2.25 per share, or 3.98%, to close at $54.25 per share on June 14, 2021.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the Boston Beer class action go to: https://bespc.com/cases/SAM
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Ventures, Generac, and Longeveron and Encourages Investors to Contact the Firm

Thursday, September 23, 2021 - 2:02am

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the Companys share price fell $29.08, or 46%, to close at $33.50 per share on August 4, 2021, on unusually heavy trading volume.
  • For more information on the Longeveron class action go to: https://bespc.com/cases/LGVN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.